Overview
Autosomal recessive spondylocostal dysostosis (SCDO) is a group of rare genetic skeletal disorders characterized by multiple vertebral segmentation defects and rib anomalies. The condition is also known as jarcho-Levin syndrome (though this term has been used more broadly), and specific subtypes include SCDO types 1 through 6, caused by mutations in genes involved in the Notch signaling pathway, including DLL3 (SCDO1), MESP2 (SCDO2), LFNG (SCDO3), HES7 (SCDO4), TBX6 (SCDO5), and RIPPLY2 (SCDO6). These genes play critical roles in somitogenesis — the embryonic process that forms the vertebrae and ribs. The hallmark features of autosomal recessive SCDO include multiple contiguous vertebral segmentation abnormalities (hemivertebrae, butterfly vertebrae, vertebral fusions, and bars) along with malaligned and fused ribs. This results in a shortened trunk with a disproportionately short stature, while limb length is typically normal. The rib abnormalities can lead to a small, rigid thorax, which may cause restrictive lung disease and respiratory insufficiency, particularly in the neonatal period and infancy. Affected individuals may also develop scoliosis or kyphoscoliosis that can worsen with growth. The condition is typically apparent at birth or prenatally on ultrasound. There is currently no cure for autosomal recessive spondylocostal dysostosis. Treatment is supportive and multidisciplinary, focusing on managing respiratory complications, which are the primary source of morbidity and mortality, especially in infancy. Respiratory support, including mechanical ventilation in severe cases, may be necessary. Orthopedic management of progressive scoliosis may include bracing or surgical intervention such as growing rod techniques. With appropriate respiratory care, many individuals survive into adulthood. Genetic counseling is recommended for affected families, and prenatal diagnosis is possible when the causative mutation is known.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Autosomal recessive spondylocostal dysostosis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Autosomal recessive spondylocostal dysostosis at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Autosomal recessive spondylocostal dysostosis.
Community
No community posts yet. Be the first to share your experience with Autosomal recessive spondylocostal dysostosis.
Start the conversation →Latest news about Autosomal recessive spondylocostal dysostosis
No recent news articles for Autosomal recessive spondylocostal dysostosis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Autosomal recessive spondylocostal dysostosis
What is Autosomal recessive spondylocostal dysostosis?
Autosomal recessive spondylocostal dysostosis (SCDO) is a group of rare genetic skeletal disorders characterized by multiple vertebral segmentation defects and rib anomalies. The condition is also known as jarcho-Levin syndrome (though this term has been used more broadly), and specific subtypes include SCDO types 1 through 6, caused by mutations in genes involved in the Notch signaling pathway, including DLL3 (SCDO1), MESP2 (SCDO2), LFNG (SCDO3), HES7 (SCDO4), TBX6 (SCDO5), and RIPPLY2 (SCDO6). These genes play critical roles in somitogenesis — the embryonic process that forms the vertebrae a
How is Autosomal recessive spondylocostal dysostosis inherited?
Autosomal recessive spondylocostal dysostosis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Autosomal recessive spondylocostal dysostosis typically begin?
Typical onset of Autosomal recessive spondylocostal dysostosis is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Autosomal recessive spondylocostal dysostosis?
2 specialists and care centers treating Autosomal recessive spondylocostal dysostosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.